Prazer Therapeutics
PrivateLast Round
Series B
Apr 1, 2025
Est. Valuation
$79.1M
Total Funding Raised
$42.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Prazer Therapeutics is a biotechnology company developing innovative therapeutics for various intractable diseases using its proprietary targeted protein degradation (TPD) platform called SPiDEM.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Prazer Therapeutics Comparables
Compare Prazer Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pin Therapeutics | 90% | |
| AUTOTAC Bio | 88% | |
| Amphista Therapeutics | 87% | |
Prazer Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 1, 2025 | ||||
| Series A | Mar 8, 2021 | ||||
| Series A | Dec 23, 2020 |
Key People
Founding team and executive leadership
Prazer Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| K2 Investment Partners | Series B |
| Smilegate Investment | Series B, Series A |
| Premier Partners | Series B |
| QUAD Investment Management | Series B |
| Company K Partners | Series B, Series A |
| Kiwoom Investment | Series B, Series A |
| Mirae Asset Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 26, 2026
Grew 32% QoQ from 19 to 25 employees.
- Apr 18, 2026
Monthly visitors grew 91% MoM, reaching 7K.
Prazer Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Prazer Therapeutics's valuation, stock price, and market status.